The findings suggest that the active compound MDRN may exert therapeutic effects on MI-induced HF by activating the PI3K/AKT/mTOR signaling pathway, inhibiting inflammatory response, and reducing oxidative stress, thus improving mitochondrial membrane potential. The gene discussed is AKT1; the disease is hydrops fetalis.